Drug rejected by FDA for having ‘difficult’ name

The makers of a new drug for rheumatoid arthritis have hit an unexpected snag after the FDA rejected it for having a name that nobody can pronounce.

Tel Aviv-based Avinyon Technologies said it was “puzzled and disappointed” about the FDA’s refusal to accept a new drug application for its RA drug nilulnulmumab.

The FDA’s Rheumatoid and Autoimmune Diseases Advisory Panel voted unanimously against accepting an application for a biologics license for nilulnulmumab, with panel chairman Dr Huhti Typeris saying the name had defied the efforts all members of